Newsroom

Glioblastoma Awareness Day Campaign Raises More Than $530K

Barrow Neurological Foundation and the Ivy Brain Tumor Center at Barrow Neurological Institute led a fundraising effort that raised more than $539,000 for brain cancer research on the first ever Glioblastoma Awareness Day, July 17, 2019. Glioblastoma, also known as GBM, is the most common and deadly form of brain cancer.

Read More

Clinical Trial Identifies New Breast Cancer Drug as a Potential Therapy for Glioblastoma

Source: Press Release

Results from the trial show that ribociclib is uniquely capable of breaking through the blood-brain barrier, a critical obstacle that for years has stalled drug development in brain tumor patients, and that the drug effectively hits its molecular target in cancer cells. The experimental Phase 0 clinical trial design also identifies a potential mechanism of drug resistance, which the Ivy Brain Tumor Center clinical trials team is now exploiting as part of an ongoing drug cocktail trial for recurrent glioblastoma patients.

Read More

By Targeting Each Patient’s Unique Tumor, Precision Medicine Is Crushing Once-Untreatable Cancers.

Source: Newsweek

Newsweek’s latest cover story examines the rising success of precision medicine to fight once-untreatable tumors and highlights our efforts in using this method to fight glioblastoma where speed and personalization are key.

Read More

Could Karyopharm’s newly approved multiple myeloma drug also work in glioblastoma?

Source: FierceBiotech

The Ivy Brain Tumor’s goal is to try to speed advances into the clinic by testing potential therapies on tumor samples taken from patients who are currently battling glioblastoma—an approach its researchers hope will shed some light on the potential of Karyopharm’s new drug in treating the disease.

Read More

Ivy Brain Tumor Center and Karyopharm Therapeutics Collaborate to Develop Tissue-Based Clinical Trial for Brain Cancer

Source: Press Release

The Ivy Brain Tumor Center will employ Karyopharm’s first-in-class oral Selective Inhibitor of Nuclear Export (SINE) compound, selinexor, in combination with other new-in-class drugs, as a dual-drug experimental therapy for adult glioblastoma.

Read More

The Ivy Brain Tumor Center takes a ‘high risk, high reward’ approach to brain cancer trials

Source: MedCity News

“For anyone in the field, what strikes them initially is the graveyard of failed therapeutics over the past thirty years, and the fact that you have a group of extremely smart resourceful and motivated scientists that just haven’t yet touched on durable treatments. As someone treating patients everyday it’s disheartening not to be able to offer them a precision therapy,” Sanai said.

“That was the concept behind the Ivy Center, we wanted to create efforts that would reduce the obstacles available for industry and drug development and getting new drugs to patients.”

Read More

New Study Makes Important Step Toward Treatment of Deadly Brain Cancer

Source: Press Release

A new Ivy Brain Tumor Center study finds that recently-approved drug ribociclib may be an important part of treatment for glioblastoma, one of the deadliest cancers in the world.

Read More

Close Menu